The invention provides a method for determining the state of charge (SOC) of an electrolyte, such as an electrolyte within a flow battery, by measuring the bulk magnetic susceptibility of the electrolyte. The method includes the step of measuring the magnetic susceptibility of an electrolyte in a measurement region and determining the state of charge of the electrolyte based on the magnetic susceptibility of the electrolyte.
G01R 31/387 - Détermination de la capacité ampère-heure ou de l’état de charge
G01N 27/76 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant des variables magnétiques des fluides par recherche de la susceptibilité
H01M 8/18 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible à régénération, p.ex. batteries à flux REDOX ou éléments à combustible secondaires
2.
METHOD OF TREATMENT OF MALARIA BY TARGETTING OPEN READING FRAMES
The present application features methods of diagnosing treating malaria by targeting novel open reading frames in Plasmodium falciparum. The novel open reading frames (nORFs) associated with malaria are expressed in a mosquito and in a human
Disclosed herein include methods, compositions, culture media, and devices for in vitro culture of synthetic embryos from mammalian pluripotent stem cells. The in vitro embryo model is generated with embryonic and extraembryonic lineages derived from embryonic stem cells through transcription-factor-mediated reprogramming and can undergo advanced development to late headfold stages.
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12M 3/04 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus comportant des moyens fournissant des couches minces
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
4.
Transplantation of Liver Cells by Administration to the Biliary Tree of the Liver
This invention relates to in vitro and in vivo methods for engrafting liver cells, such as cholangiocytes, into a liver comprising administering the liver cells to the biliary tree of the liver. The liver cells may be in the form of aggregates and may be administered in the direction of decreasing biliary duct diameter. This may be useful for example for the treatment of an individual with a diseased or damaged liver.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
5.
METHODS AND COMPOSITIONS FOR GENERATING EMBRYOS IN VITRO FROM PLURIPOTENT STEM CELLS
Disclosed herein include methods, compositions and culture media for generating synthetic embryos in vitro from mammalian pluripotent stem cells such as pluripotent embryonic stem cells. In some embodiments, the method can comprise co-culturing a wild-type mammalian pluripotent stem cell and modified mammalian pluripotent stem cells comprising one or more genes encoding transcription factors that can drive generation of extraembryonic cells or extraembryonic-like cells (e.g., GATA6 gene, SOX17 gene, GATA3 gene and/or TFAP2C gene) under a condition in a culture medium allowing the pluripotent stem cells to self-organize into a post-implantation embryo structure. In some embodiments, the pluripotent embryonic stem cells are human pluripotent embryonic stem cells and the generated synthetic embryo is a human embryo.
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
C12M 1/32 - Inoculateur ou échantillonneur du type à champs multiples ou en continu
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The invention relates to a method of preparing a nucleic acid library from a sample comprising high molecular weight DNA (HMW DNA), preferably genomic DNA, comprising the steps (i) contacting said DNA with a first restriction enzyme and a second restriction enzyme; (ii) contacting said DNA with a pair of oligonucleotide adapters according to any of claims 1 to 12; (iii) contacting said DNA with at least one DNA ligase; and (iv) incubating to allow digestion of the DNA by said first restriction enzyme and second restriction enzyme, annealing of said oligonucleotide adapters to the digested DNA, and ligation of the annealed oligonucleotide adapters to the digested DNA by said at least one DNA ligase. The invention also relates to oligonucleotide adapters, a kit, and uses of same.
International Centre for Genetic Engineering and Biotechnology (Inde)
Inventeur(s)
Prabakaran, Sudhakaran
Abrégé
The present application features methods of treating a cancer associated with a genetic variant. The genetic variant is also present within a novel open reading frame (nORF) associated with the gene in which the variant leads to increased or reduced expression of the variant nORF.
International Centre for Genetic Engineering and Biotechnology (Royaume‑Uni)
Inventeur(s)
Prabakaran, Sudhakaran
Abrégé
The present application features methods of treating a cancer associated with a dysregulated novel open reading frame (nORF) in which increased or reduced expression of the dysregulated nORF is associated with cancer.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
The present application relates to metal-organic framework (MOF) nanoparticles, in particular, coated MOF nanoparticles, methods of manufacturing said coated MOF nanoparticles, and uses of said coated MOF nanoparticles.
International Centre for Genetic Engineering and Biotechnology (Inde)
Inventeur(s)
Prabakaran, Sudhakaran
Abrégé
The present application features methods of treating a disease associated with a genetic variant. The genetic variant is also present within a novel open reading frame (nORF) associated with the gene in which the variant encodes either the gain or loss of a stop codon.
The invention relates to a polypeptide selected from bone morphogenetic protein 10 (BMP10), or a bone morphogenetic protein 9 (BMP9) variant lacking osteogenic activity, for use in the treatment of a vascular disease or a respiratory disease. The invention also relates to novel BMP9 variants and to pharmaceutical compositions comprising said polypeptides.
The present invention provides novel DNA molecules and constructs, including their nucleotide sequences, useful for expressing proteins in plants to promote symbiotic infection. The invention also provides plants and plant cells transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides, along with methods of their use.
A computer implemented method of predicting liquid-liquid phase separation LLPS) behaviour of a biomolecule, the method comprising: inputting information identifying the biomolecule and its environmental composition and/or chemical modification of the biomolecule to an algorithm configured to predict, whether the biomolecule will exhibit LLPS under specified environmental conditions and/or chemical modification of the biomolecule, wherein: the algorithm is an algorithm generated by machine learning trained on data featurised according to features relating to biomolecules in the training data and features relating to the environmental conditions and/or chemical modification of the biomolecules in the training data, and the algorithm outputs a prediction of whether the biomolecule will exhibit LLPS under the specified environmental conditions and/or chemical modification of the biomolecule.
The invention provides a method for labeling a nucleic acid comprising N6-methyl adenine. The method comprises forming an alpha-amino radical on the N6-methyl group of N6mAde, and capturing the alpha-amino radical with a radical acceptor comprising a nitrosopyridyl group. The presence of N6mAde in a nucleic acid may then be established by detection of the labeled nucleic acid, or the labeled nucleic acid may be extracted or further modified using the label. Also provided is a method for mapping the position of N6mAde within a target nucleic acid, and probe molecules and kits for use in the method.
C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p.ex. séquençage par hybridation [SBH]
C12Q 1/6818 - Tests d’hybridation caractérisés par les moyens de détection impliquant l’interaction de plusieurs marqueurs, p.ex. transfert d’énergie de résonance
C07D 213/61 - Atomes d'halogènes ou radicaux nitro
C07D 213/75 - Radicaux amino ou imino, acylés par un acide carboxylique, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p.ex. des carbamates
15.
Composite Layers, Methods for Their Manufacture and Uses Thereof
A composite layer of carbon nanotubes and metal such as copper is formed by electrodeposition. The layer has a thickness of at least 10 μm. The carbon nanotubes are distributed through the layer and are present in the layer at a volume fraction of at least 0.001 vol % and at most 65 vol %. The volume fraction is based on the total volume of the metal and carbon nanotubes and not including any pore volume. The carbon nanotubes are substantially uniformly plated with the metal. The composite layer has a density ratio satisfying Player Pmetal ≤0.35 where player is the bulk density of the composite layer of thickness of at least 10 μm, including any voids that are present in the composite layer and pmetal is the volumetric mass density material property of the metal. The composite layer is of use in evaporation-condensation apparatus, as an active material layer in an electrochemical device or in an electroforming process.
C25D 13/02 - Revêtement électrophorétique caractérisé par le procédé avec des matières inorganiques
F28D 15/04 - Appareils échangeurs de chaleur dans lesquels l'agent intermédiaire de transfert de chaleur en tubes fermés passe dans ou à travers les parois des canalisations dans lesquels l'agent se condense et s'évapore, p.ex. tubes caloporteurs avec des tubes ayant une structure capillaire
A microfluidic sensor comprising: a first substrate; a second substrate; a cavity formed between the first substrate and the second substrate, the cavity comprising a reservoir portion and a channel portion extending from the reservoir portion; a capacitive element disposed between the first substrate and the second substrate, the capacitive element being at least partially disposed in the channel portion of the cavity; and a dielectric sensing liquid provided in the reservoir portion. Upon application of a force to the first substrate adjacent the reservoir portion, the reservoir portion is configured to deform and displace the sensing liquid along the channel portion, so as to change the capacitance of the capacitive element within the channel portion.
A61F 2/46 - Outils particuliers pour l'implantation des articulations artificielles
G01L 1/14 - Mesure des forces ou des contraintes, en général en mesurant les variations de la capacité ou de l'inductance des éléments électriques, p.ex. en mesurant les variations de fréquence des oscillateurs électriques
G01L 1/02 - Mesure des forces ou des contraintes, en général par des moyens hydrauliques ou pneumatiques
B81B 3/00 - Dispositifs comportant des éléments flexibles ou déformables, p.ex. comportant des membranes ou des lamelles élastiques
An image generation system for providing a ghost image free head-up display, the system comprising a display screen having a front surface and a back surface, a picture generation unit for projecting an image towards the display screen for reflection towards an eye box, a field lens, and an anisotropic optical component having a first optical power along a first axis and second optical power along a second axis, wherein the first and second axis are perpendicular, wherein the picture generation unit is configured to project light through the field lens such that light is incident on the front surface of the display screen forming a first virtual image, wherein a portion of the light is transmitted through the display screen and is incident on the back surface of the display screen forming a second virtual image, wherein the first and second virtual images are offset along the first axis, wherein the field lens is configured to project the first virtual image at a first projection distance and the second virtual image at a second projection distance such that the offset is below a threshold magnitude and the first and second virtual images are substantially overlaid as viewed from the eye box, and wherein the anisotropic optical component is configured to magnify the first and second virtual image along the second axis only.
The present invention concerns methods of diagnosing and/or prognostication of non-alcoholic fatty liver disease (NAFLD) or alcohol-related fatty liver disease (ARLD) in a subject, wherein said methods comprise detecting somatic mutations in DNA, RNA and/or protein that confer a selective advantage on one or more liver cells of the subject. The present invention also provides methods for identifying subjects suffering from NAFLD or ARLD who would benefit from treatment with a therapeutic agent and/or identifying subjects suffering from NAFLD or ARLD who would benefit from increased disease monitoring. The present invention also provides therapeutic agents that find utility in the treatment of NAFLD or ARLD.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
The present invention relates to plant-based microcapsules for the efficient encapsulation and retention of water-soluble ingredients, as well as the efficient co-encapsulation of water-soluble and water-insoluble ingredients. The present invention also relates to compositions comprising the microcapsules, a method of making the microcapsules and compositions, and to uses of the microcapsules and compositions.
A23D 7/005 - Compositions à base d'huiles ou de graisses comestibles, contenant une phase aqueuse, p.ex. margarines caractérisées par des ingrédients autres que des triglycérides d'acides gras
The disclosure provides a PKC inhibitor and a cytotoxic agent for use in therapy, wherein the PKC inhibitor reaches a peak concentration in a subject prior to the cytotoxic agent reaching a peak concentration. The PKC inhibitor and the cytotoxic 5 agent may be used to treat cancer or an autoimmune disease.
A61K 31/4545 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pipampérone, anabasine
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p.ex. kétorolac, physostigmine
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. loxapine, staurosporine
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p.ex. benzimidazoles
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p.ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p.ex. sulfadiazine
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p.ex. adénosine, acide adénylique
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
The invention relates to microfluidic methods; and modular devices and systems for implementing the methods. The invention also relates to uses of these devices and systems for biological analyses.
The present invention relates to adeno-associated virus (AAV) capsid proteins that have been modified to insert an amino acid sequence and/or methods of targeting microglia or brain macrophages using the AAV capsid proteins of the invention.
A method of characterizing one or more particles in a fluid, e.g. a liquid, using interferometric scattering optical (iSCAT) microscopy. The method involves illuminating a region of a fluid using an objective lens so that light is scattered by one or more particles in the fluid. The scattered light and reference light are captured using the objective lens and interfere at an imaging device. A succession of images of the interference is processed to determine image correlation values which define a gradual decorrelation over time from which a property of the particle(s) is determined.
G03H 1/00 - Procédés ou appareils holographiques utilisant la lumière, les infrarouges ou les ultraviolets pour obtenir des hologrammes ou pour en obtenir une image; Leurs détails spécifiques
G03H 1/04 - Procédés ou appareils pour produire des hologrammes
24.
MODULAR MICROFLUIDIC DEVICES, SYSTEMS AND METHODS FOR TOTAL RNA ANALYSES
KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (Pays‑Bas)
Inventeur(s)
Hollfelder, Florian
Kaminski, Tomasz
De Jonghe, Joachim
Salmen, Fredrik
Van Oudenaarden, Alexander
Abrégé
Modular microfluidic devices, systems and methods for total RNA analyses The invention relates to microfluidic methods of preparing a sequencing library for analyses of total RNA. The invention also relates to modular microfluidic systems for carrying out these methods.
A magnetic particle (30, 70) has a layered structure (6, 56) between a top surface of the particle and an opposed bottom surface of the particle. Layers of the structure include one or more non- magnetic layer(s) and one or more magnetized layer(s). The ratio of a lateral dimension of the one or more magnetized layers to the aggregate thickness of the magnetized layer or layers is greater than 500. A plurality of such magnetic particles (30, 70) can be functionalised and marked with readable codes (16, 66) corresponding to the functionalisation, for use for performing assays such as bioassays.
H01F 10/26 - Pellicules magnétiques minces, p.ex. de structure à un domaine caractérisées par le substrat ou par les couches intermédiaires
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
26.
SYNTHESIS OF HIGH MOLECULAR WEIGHT AND STRENGTH POLYISOBUTYLENE-BASED POLYURETHANES AND USE THEREOF
A method of preparing a polyisobutylene-based polyurethane for making heart valves is disclosed, wherein the method includes providing a polyisobutylene (PIB) polymer, freshly distilling a diisocyanate compound to create a freshly distilled diisocyanate and providing a chain extender. When the polyisobutylene polymer, the freshly distilled diisocyanate, and the chain extender are combined together by mixing, the created polyisobutylene-based polyurethane exhibits a higher number average molecular weight, a higher ultimate strength, a higher elongation, and a greater toughness than a polyisobutylene-based polyurethane made without a freshly distilled diisocyanate, which makes the polymer particularly useful as a bioprosthetic heart valve.
C08G 18/64 - Composés macromoléculaires non prévus dans les groupes
C08G 18/76 - Polyisocyanates ou polyisothiocyanates cycliques aromatiques
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
The present invention provides methods for the non-enzymatic cleavage of target nucleic acids, for example for use in epigenomic and epitranscriptomic mapping and therapy. The method comprises contacting a target nucleic acid molecule with a bifunctional probe comprising a cleavage group and a covalent binding group such that the bifunctional probe covalently binds to the target nucleic acid molecule and cleaves the 5 target nucleic acid molecule bound thereto. Also provided is a method of selectively cleaving a target nucleic acid in a cell, a method for determining the modification of nucleic acid molecules by a nucleic acid modification enzyme in a cell, and a bifunctional probe for use in the methods.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A carrier system (100) provides a carrier or carriers (12) for carrying assay samples in an assay. The carrier(s) are secured to a substrate (10) by a release layer (14). The carrier(s) are suitable for receiving an assay sample, and the release layer is configured to release the carrier(s) from the substrate in the presence of a biocompatible aqueous solution. To perform an assay a biocompatible aqueous solution, in which the assay sample is usually suspended, is supplied to the carrier system. The assay sample is received by the carrier(s) and the release layer is activated by the biocompatible aqueous solution to release the carrier.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
29.
Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof
Provided are a compound of the formula:
(5-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethoxy)benzo[c][2,6]naphthyridine-8-carboxylic acid) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the above compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
The present invention relates to a siloxane-based liquid crystalline elastomer, preferably an exchangeable siloxane-based liquid crystalline elastomer, derived from monomers (A1), (B1) and (C1), wherein (C1) is an acyclic or cyclic vinyl siloxane, and (A1) and (B1) have the following formulae:
The present invention relates to a siloxane-based liquid crystalline elastomer, preferably an exchangeable siloxane-based liquid crystalline elastomer, derived from monomers (A1), (B1) and (C1), wherein (C1) is an acyclic or cyclic vinyl siloxane, and (A1) and (B1) have the following formulae:
The present invention relates to a siloxane-based liquid crystalline elastomer, preferably an exchangeable siloxane-based liquid crystalline elastomer, derived from monomers (A1), (B1) and (C1), wherein (C1) is an acyclic or cyclic vinyl siloxane, and (A1) and (B1) have the following formulae:
wherein is a mesogen, and
Rx and Ry are independently selected from hydrogen or substituted or unsubstituted C1-12 alkyl;
The present invention relates to a siloxane-based liquid crystalline elastomer, preferably an exchangeable siloxane-based liquid crystalline elastomer, derived from monomers (A1), (B1) and (C1), wherein (C1) is an acyclic or cyclic vinyl siloxane, and (A1) and (B1) have the following formulae:
wherein is a mesogen, and
Rx and Ry are independently selected from hydrogen or substituted or unsubstituted C1-12 alkyl;
The present invention relates to a siloxane-based liquid crystalline elastomer, preferably an exchangeable siloxane-based liquid crystalline elastomer, derived from monomers (A1), (B1) and (C1), wherein (C1) is an acyclic or cyclic vinyl siloxane, and (A1) and (B1) have the following formulae:
wherein is a mesogen, and
Rx and Ry are independently selected from hydrogen or substituted or unsubstituted C1-12 alkyl;
wherein is an organic group.
C08G 77/52 - Composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant du silicium, avec ou sans soufre, azote, oxygène ou carbone dans lesquels au moins deux atomes de silicium, mais pas la totalité, sont liés autrement que par des atomes d'oxygène par des liaisons au carbone contenant des cycles aromatiques
31.
METHODS, CULTURE MEDIAS AND DEVICES FOR GENERATING EMBRYOS IN VITRO FROM STEM CELLS
Disclosed herein include methods and compositions for culture medias for in vitro culture of synthetic embryos from mammalian pluripotent stem cells and extra-embryonic stem cells. The methods and compositions described herein can generate synthetic embryos at different developmental stage reaching early organogenesis and beyond. Disclosed herein also include an embryo culturing system and methods of using same.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
Articles comprising a surface or porous substrate and having on said surface or porous substrate a coating comprising microfibrillated cellulose or nanocellulose, methods of applying a coating comprising microfibrillated cellulose or nanocellulose to a surface or porous substrate, compositions comprising microfibrillated cellulose or nanocellulose, and the use of such compositions in methods of preparing an antimicrobial surface coating, and improving filtration efficiency and preparing an antimicrobial surface and/or antiviral surface coating.
The present invention is directed to methods and devices capable of target analyte separation and analysis, in particular highly sensitive separation and detection and free-solution analyte detection assays.
An apparatus for characterising a biomolecule is provided. The apparatus comprising a sample inlet channel configured to introduce a sample fluid including the biomolecule to the apparatus; an auxiliary inlet channel configured to introduce an auxiliary fluid to the apparatus; a distribution channel in fluid communication with the sample inlet channel and the auxiliary inlet channel; wherein the distribution channel is adapted to generate a distribution of biomolecules; a measurement module configured to detect a signature profile of the biomolecule to obtain a measured dataset of the detected biomolecule; a storage location configured to store and maintain a stored dataset comprising a plurality of parameters that are associated with the measured dataset obtained from the measurement module; and an analysis module configured to receive the stored dataset from the storage location and correlate the stored dataset with the measured dataset from the measurement module to provide a correlation value, wherein the analysis module is further configured to use the correlation value to determine at least two characteristics of the biomolecule simultaneously using Bayesian analysis. A method for characterising a biomolecule is also provided.
G01N 33/558 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
36.
METHOD AND APPARATUS FOR MEASURING PHASE TRANSITION CHARACTERISTICS OF MACROMOLECULES
A method measuring the phase transition characteristics of a macromolecule, the method comprising: generating a stream of micro-droplets comprising at least one constituent, of which one constituent comprises the macromolecule, varying the conditions in the micro-droplets; and measuring the relative concentrations of the constituents of, and the phases of the macromolecule present in, the micro-droplets.
Various methods of additive layer manufacturing, and objects obtainable by such manufacturing, are disclosed. In particular, there is provided a method of additive layer manufacturing comprising depositing a layer of a material on a surface, and controlling the deposition to vary a material property of the material within the layer. There is also provided a method of additive layer manufacturing comprising depositing at least one layer of material on a sacrificial layer, the layer of material having a thickness of 400 microns or less, wherein the sacrificial layer is located on a base surface.
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p.ex. modélisation par dépôt de fil en fusion [FDM]
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
The present invention relates to the field of cancer progression. The invention provides in vivo methods for preventing or inhibiting the migration of cancer cells away from the site of a tumour or a resected tumour, thus inhibiting invasion and metastasis, by contacting all or part of the tumour or resected tumour, or all or part of the vicinity of the tumour, with an agent which impedes the migration and/or proliferation of cancer cells, such as a cross-linking agent.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p.ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/132 - Amines, p.ex. amantadine ayant plusieurs groupes amino, p.ex. spermidine, putrescine
An organic light emitting device, comprising an anode; a cathode; and an emissive layer between the anode and the cathode, wherein the emissive layer comprises a first material which is an organic semiconductor compound and a second material which is a different organic semiconductor compound that has a spin doublet ground state; and wherein a lowest spin singlet excitation energy of the first material and a lowest spin triplet excitation energy of the first material are greater than a lowest spin doublet excitation energy of the second material; a method of fabricating an organic light emitting device, comprising: forming an emissive layer between an anode and a cathode, wherein the emissive layer comprises a first material which is an organic semiconductor compound and a second material which is a different organic semiconductor compound that has a spin doublet ground state; and wherein a lowest spin singlet excitation energy of the first material and a lowest spin triplet excitation energy of the first material are greater than a lowest spin doublet excitation energy of the second material; and a method of operating the device by applying a voltage across the device, such that spin singlet excited states and spin triplet excited states are formed for the first material, wherein energy is transferred from spin singlet excited states in the first material and spin triplet excited states in the first material to form spin doublet excited states in the second material, wherein the second material emits fluorescent light when transitioning from a spin doublet excited state to a ground state.
H01L 51/50 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés pour l'émission de lumière, p.ex. diodes émettrices de lumière organiques (OLED) ou dispositifs émetteurs de lumière à base de polymères (PLED)
H01L 51/00 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives
40.
Nucleic Acid and Other Compositions and Methods for the Modulation of Cell Membranes
The Board of Trustees of the University of Illinois (USA)
Cambridge Enterprise Limited (Royaume‑Uni)
Inventeur(s)
Aksimentiev, Aleksei
Keyser, Ulrich F.
Abrégé
The present invention provides compositions and methods for transferring phospholipids and other molecules between the leaflets of a cell membrane. The compositions comprise at least one nucleic acid or compound having a hydrophilic region, where the composition is able to form a nanostructure that forms a toroidal pore in a lipid membrane. The nucleic acid or hydrophilic region-containing compound further contains an attached molecule capable of inserting the nanostructure into the lipid membrane. The invention also provides methods for scrambling lipids and other molecules in a cell membrane, which can be used to alter the function of a selected cell or to facilitate the death of the cell. The scrambling activity of synthetic scramblases described herein outperforms previously known enzymatically active DNA nanostructures and naturally occurring scramblases, in some cases by several orders of magnitude.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
41.
METHOD FOR ELECTROCHEMICALLY ETCHING A SEMICONDUCTOR STRUCTURE
A method for etching a semiconductor structure (110) is provided, the semiconductor structure comprising a sub-surface quantum structure (30) of a first III-V semiconductor material, beneath a surface layer (31) of a second III-V semiconductor material having a charge carrier density of less than 5 × 1017 cm-3. The sub-surface quantum structure may comprise, for example, a quantum well, or a quantum wire, or a quantum dot. The method comprises the steps of exposing the surface layer to an electrolyte (130), and applying a potential difference between the first III-V semiconductor material and the electrolyte, to electrochemically etch the sub-surface quantum structure (30) to form a plurality of nanostructures, while the surface layer (31) is not etched. A semiconductor structure, uses thereof, and devices incorporating such semiconductor structures are further provided.
H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
H01L 33/02 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs
H01L 33/06 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs ayant une structure à effet quantique ou un superréseau, p.ex. jonction tunnel au sein de la région électroluminescente, p.ex. structure de confinement quantique ou barrière tunnel
H01L 33/10 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs ayant une structure réfléchissante, p.ex. réflecteur de Bragg en semi-conducteur
H01L 33/32 - Matériaux de la région électroluminescente contenant uniquement des éléments du groupe III et du groupe V de la classification périodique contenant de l'azote
42.
METHOD FOR POROSIFYING A MATERIAL AND SEMICONDUCTOR STRUCTURE
A method for porosifying a III-nitride material in a semiconductor structure is provided, the semiconductor structure comprising a sub-surface structure of a first III-nitride material, having a charge carrier density greater than 5×1017 cm−3, beneath a surface layer of a second III-nitride material, having a charge carrier density of between 1×1014 cm−3 and 1×1017 cm−3. The method comprises the steps of exposing the surface layer to an electrolyte, and applying a potential difference between the first III-nitride material and the electrolyte, so that the sub-surface structure is porosified by electrochemical etching, while the surface layer is not porosified. A semiconductor structure and uses thereof are further provided.
Liquid dressing compositions liquid for veterinary use in the treatment or prevention of infection and/or wounds are described that comprise shellac, an anti-infective metal active and a solvent. The compositions are capable of forming a barrier when topically applied to a non-human animal subject, providing an easily applied barrier for protecting lesions and other wounds from external infective agents in a veterinary setting.
A sensor for use in biosensing is disclosed. The sensor comprises a photonic crystal waveguide comprising a photonic crystal comprising holes in a layer of dielectric material and a waveguide in the photonic crystal. The sensor comprises at least one strip disposed on the photonic crystal waveguide, spaced apart along, and running across the photonic crystal waveguide so as to form respective strip cavities, each of the at least one strip including a respective layer of material for sensing presence of a respective analyte; and a slot running along the waveguide of the photonic crystal waveguide.
G02B 6/122 - Elements optiques de base, p.ex. voies de guidage de la lumière
G02B 6/12 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES - Détails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p.ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
The invention provides a CCR1 antagonist, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of pancreatic cancer, in particular a CCR1 antagonist, for example in combination with one or more further therapeutic agents effective as anti-tumour agents in the treatment of pancreatic cancer. Such an anti-tumour agent may be a chemotherapeutic agent selected from Gemcitabine, Fluorouracil (5-FU), Capecitabine, FOLFIRINOX (Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride and Oxaliplatin), Nab-paclitaxel (Abraxane®) and combinations thereof. An immuno-oncology agent (e.g. a PD-1 inhibitor and/or a PD-L1 inhibitor) may also favourably be used with the CCR1 antagonist.
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
The present invention relates to sensors for detecting the presence or measuring the concentration of a target analyte, the sensor comprising: (i) a first phase comprising a first crosslinked polymer; (ii) a second phase comprising a second crosslinked polymer; and (ill) a target analyte recognition agent; the first phase and second phase arranged to form an optical grating. The first crosslinked polymer comprises low amounts of a crosslinking agent. The present invention also relates to methods of making a sensor for detecting the presence or measuring the concentration of a target analyte.
G01N 21/45 - Réfringence; Propriétés liées à la phase, p.ex. longueur du chemin optique en utilisant les méthodes de Schlieren
G01N 21/77 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique
47.
Method For the Preparation of Single-Walled Carbon Nanotubes
The present invention relates to the production of a carbon material (eg a carbon nanomaterial) comprising single-walled carbon nanotubes (SWCNTs) and to the carbon material per se.
Disclosed herein include systems, devices, and methods for detecting embryo polarization from a 2D image generated from a 3D image of an embryo that is not fluorescently labeled using a convolutional neural network (CNN), e.g., deep CNN.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
The invention relates to in vitro methods for isolating, or producing selected populations of human epicardial cells derived from human pluripotent stem cells; defined mixtures of said cells, and therapeutic uses thereof. Said population comprises epicardial cells with or without the potential to differentiate into cardiac fibroblasts, or a mixture thereof.
The present invention relates to salts and compositions for use in the treatment of ischaemic stroke reperfusion (IR) injury. In particular, the present invention relates to a salt of formula (I) for use in treating or preventing ischaemic stroke reperfusion injury, wherein X, Y, n, m, Z, A and B are as defined herein.
A61K 31/194 - Acides carboxyliques, p.ex. acide valproïque ayant plusieurs groupes carboxyle, p.ex. acides succinique, maléique ou phtalique
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
Oxford University Innovation Limited (Royaume‑Uni)
Cambridge Enterprise Limited (Royaume‑Uni)
Inventeur(s)
Dar, Ghulam Hassan
Wood, Matthew
Baker, Roger A.
Kuan, Wei-Li
Abrégé
The present invention relates to compositions for the delivery of molecules such as a peptide, a nucleic acid and/or a small molecule drug. In particular, the present invention relates to an extracellular vesicle (EV) loaded with a peptide, a nucleic acid and/or a small molecule drug, along with methods of producing said EV.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p.ex. séquences de liaison peptidiques vulnérable aux protéases
An image generation system for providing a ghost image free head-up display, the system comprising a display screen having a front surface and a back surface, a picture generation unit for projecting an image towards the display screen for reflection towards a predetermined eye box, and a field lens, wherein the picture generation unit is configured to project light through the field lens such that light is incident on the front surface of the display screen forming a first virtual image, wherein a portion of the light is transmitted through the display screen and is incident on the back surface of the display screen forming a second virtual image, wherein the first and second virtual images have an offset, wherein the field lens is configured such that the offset is below a threshold magnitude and the first and second virtual images are substantially overlaid as viewed from the eye box.
G02B 30/33 - Systèmes ou appareils optiques pour produire des effets tridimensionnels [3D], p.ex. des effets stéréoscopiques en fournissant des première et seconde images de parallaxe à chacun des yeux gauche et droit d’un observateur du type autostéréoscopique comprenant des sources de lumière directionnelle ou des sources de rétroéclairage
G09G 3/00 - Dispositions ou circuits de commande présentant un intérêt uniquement pour l'affichage utilisant des moyens de visualisation autres que les tubes à rayons cathodiques
Provided is a detector assembly for determining a ratio of lactate to pyruvate from dialysis, said detector assembly comprising: a first pump, a dialysis probe, a first tube fluidically coupling the first pump to an inlet of the dialysis probe, an infrared (IR) detector, a second tube fluidically coupling an outlet of the dialysis probe to the IR detector, and a controller. The first pump pumps a perfusate at a first flow rate to the dialysis probe, via the first tube, and to, in turn, pump a dialysate at a second flow from the dialysis probe to the IR detector, via the second tube. The IR detector detects respective absorbances due to lactate and pyruvate in the dialysate, and the controller determines the ratio of lactate to pyruvate in the dialysate.
A61M 1/14 - Systèmes de dialyse; Reins artificiels; Oxygénateurs du sang
G01N 21/3577 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de liquides, p.ex. l'eau polluée
A method is disclosed of manufacturing a semiconductor structure comprising an (001) oriented zincblende structure group III-nitride layer, such as GaN. The layer is formed on a 3C-SiC layer on a silicon substrate. A nucleation layer is formed, recrystallized and then the zincblende structure group III-nitride layer is formed by MOVPE at temperature T3 in the range 750-1000° C., to a thickness of at least 0.5μ. There is also disclosed a corresponding semiconductor structure comprising a zincblende structure group III-nitride layer which, when characterized by XRD, shows that the substantial majority, or all, of the layer is formed of zincblende structure group III-nitride in preference to wurtzite structure group III-nitride.
H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
H01L 33/32 - Matériaux de la région électroluminescente contenant uniquement des éléments du groupe III et du groupe V de la classification périodique contenant de l'azote
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
H01L 29/04 - Corps semi-conducteurs caractérisés par leur structure cristalline, p.ex. polycristalline, cubique ou à orientation particulière des plans cristallins
H01L 29/20 - Corps semi-conducteurs caractérisés par les matériaux dont ils sont constitués comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des composés AIIIBV
A semi-volatile particulate matter detection device is disclosed for detecting semi-volatile particulate matter in a gas flow. The device has a first filter stage for receiving the gas flow, the first filter stage being configured to capture particulate matter and to be heated to a temperature of at least 150° C. to volatilise semi-volatile particulate matter to produce semi-volatile vapour for passing through the first filter stage with the gas flow. The device also has a conveyance section downstream of the first filter stage to convey the gas flow and the semi-volatile vapour. A second filter stage is configured to receive the flow from the conveyance section. The temperature of the conveyance section and/or of the second filter stage is controllable so as to cause condensation of at least some of the semi-volatile vapour and collect it on the second filter stage. A detector is provided for detecting at least one characteristic of the condensed semi-volatile vapour on the second filter stage.
A semiconductor structure comprising a matrix having a first cubic Group-III nitride with a first band gap, and a second cubic Group-III nitride having a second band gap and forming a region embedded within the matrix. The second cubic Group-III nitride comprises an alloying material which reduces the second band gap relative to the first band gap, a quantum wire is defined by a portion within the region embedded within the matrix, the portion forming a one-dimensional charge-carrier confinement channel, wherein the quantum wire is operable to exhibit emission luminescence which is optically polarised.
H01S 5/34 - Structure ou forme de la région active; Matériaux pour la région active comprenant des structures à puits quantiques ou à superréseaux, p.ex. lasers à puits quantique unique [SQW], lasers à plusieurs puits quantiques [MQW] ou lasers à hétérostructure de confinement séparée ayant un indice progressif [GRINSCH]
H01S 5/343 - Structure ou forme de la région active; Matériaux pour la région active comprenant des structures à puits quantiques ou à superréseaux, p.ex. lasers à puits quantique unique [SQW], lasers à plusieurs puits quantiques [MQW] ou lasers à hétérostructure de confinement séparée ayant un indice progressif [GRINSCH] dans des composés AIIIBV, p.ex. laser AlGaAs
H01L 33/06 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs ayant une structure à effet quantique ou un superréseau, p.ex. jonction tunnel au sein de la région électroluminescente, p.ex. structure de confinement quantique ou barrière tunnel
H01L 33/18 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs ayant une structure cristalline ou une orientation particulière, p.ex. polycristalline, amorphe ou poreuse au sein de la région électroluminescente
H01L 33/32 - Matériaux de la région électroluminescente contenant uniquement des éléments du groupe III et du groupe V de la classification périodique contenant de l'azote
H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
57.
MULTIDIMENSIONAL MICROFLUIDIC PROTEIN CHARACTERISATION
The present invention relates to the identification of proteins involving measurement and characterisation of multidimensional aspects of said proteins.
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p.ex. utilisation de bandes de papier indicateur
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
Semiconductor devices comprising: a semiconductor device comprising: a first electrode comprising conductive material, wherein the conductive material is deposited by ink deposition (for example, layered material inks such as graphene and/or graphite), or wherein the conductive material comprises CVD grown graphene or carbon nanotubes; a first charge transportation layer, wherein the first charge transportation layer is doped with the conductive material of the first electrode; an optional insulation layer; a perovskite active layer; a second charge transportation layer; and a second electrode.
H01L 51/00 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives
H01L 51/50 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés pour l'émission de lumière, p.ex. diodes émettrices de lumière organiques (OLED) ou dispositifs émetteurs de lumière à base de polymères (PLED)
The invention provides methods of diagnosing and treating multiple sclerosis (MS) patients, including methods of identifying and treating multiple sclerosis patients who are at increased risk of developing a secondary autoimmune disease following lymphocyte depletion, caused, e.g., by treatment with an anti-CD52 antibody. Also embraced are methods of selecting treatment regimens for MS patients, and reagents useful in the above methods.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
60.
METHODS OF OPTIMISING EXPRESSION AND DELIVERY OF MITOCHONDRIAL PROTEINS
The invention relates to methods for the simultaneous expression and delivery to mitochondria of two or more proteins using a single expression vector. Also described are the expression vectors and host cells comprising the vectors. Where the proteins are genome editing reagents, the invention also relates to the use of the expression vectors to alter levels of mitochondrial heteroplasmy and treat mitochondrial disorders.
The invention relates to the use of a single heavy chain variable domain antibody against human cytomegalovirus protein US28, which antibody binds to the extracellular region including, for example, the N-terminal extracellular region and/or the extracellular loops of US28, for isolation of cells that are infected with cytomegalovirus and/or for ex vivo reactivation of cytomegalovirus in latently infected cells. The invention further relates to the anti-US28 antibody for use in a method of reactivating cytomegalovirus in infected cells, or in a method of eliminating infected cells. The invention further relates to a tissue, organ, or cells such as bone marrow stem cells, from which cells that were infected with CMV have been removed with the use of the anti-US28 antibody.
C07K 16/08 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
Liquid dressing compositions liquid for use in the treatment or prevention of infection and/or wounds are described that comprise shellac, an anti-infective metal active and a solvent. The compositions are capable of forming a barrier when topically applied to a subject, providing an easily applied barrier for protecting lesions and other wounds from external infective agents.
The present invention relates to the desulfurisation of lead-containing waste. In particular, the present invention relates to a method in which lead-containing waste is desulfurised to form a desulfurised lead-containing waste material which is suitable for recycling into lead or leady oxide. The method is particularly suitable for desulfurising lead-acid battery paste.
The present invention provides a covalent-organic framework (COF) body, populations of such bodies, a method for manufacturing a covalent-organic framework (COF) body, and (a) a gas storage system or a gas separation system comprising a gas storage vessel and a population of such COF bodies. The COF body comprises a plurality of primary COF particles, some or all of the primary COF particles being agglomerated as COF agglomerates. The average diameter of the primary COF particles is between nm and 120 nm, and the average diameter of the agglomerates is larger than the average diameter of the primary COF particles and between 15 nm and 250 nm. By careful control over particle size distribution during the formation of the COF material, it is possible (b) to form COF materials into high bulk density shapes and forms which are industrially useful and practical without losing sorbent performance.
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
B01D 53/04 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p.ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
65.
METHOD AND APPARATUS FOR ANALYSING INTRACORONARY IMAGES
Embodiments of the present techniques provide apparatus and methods for analysing intracoronary images, for example to predict the likelihood of a disease, disease presentation or event, and/or to track performance of a drug or other treatment. The method may comprise: for each image in the set of images of a coronary artery: classifying the image, using a first neural network, for the presence or absence of diseased tissue; when the image is classified as having diseased tissue present, classifying the image, using a second neural network, for the presence or absence of an artefact; determining whether to analyse the image based on the classifying steps; when the image is to be analysed, analysing the image by identifying, using a third neural network, one or more features of interest in a coronary artery tissue; and measuring each identified feature of interest.
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 10/40 - Extraction de caractéristiques d’images ou de vidéos
G06V 10/774 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source méthodes de Bootstrap, p.ex. "bagging” ou “boosting”
G06V 10/766 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la régression, p.ex. en projetant les caractéristiques sur des hyperplans
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p.ex. DICOM, HL7 ou PACS
A particle sensor for measuring size and concentration properties of particles in a gas includes a bipolar diffusion charger configured to charge particles within a received gas sample by the collision of the received particles with and transfer of charge from both positive and negative ions concurrently. At least one electrometer detects the charge of received particles thereby charged. The net, positive, negative or total charge on the bipolarly charged particles has a low sensitivity to variations in the absolute rate of charge generation in the bipolar diffusion charger. A sensor for a ratio of ion charge mobilities in a bipolar diffusion charger employs an ion trap between the bipolar diffusion charger and at least one electrometer.
A medical device comprising a flexible electrode array having a bend radius of no more than about 2 mm; and a fluidic component, wherein the fluidic component is fluidically actuatable to cause the fluidic component to change configuration; wherein the fluidic component and the flexible electrode array are configured such that a change in configuration of the fluidic component causes a change in configuration of the flexible electrode array.
A61B 5/293 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG] invasives
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
The present invention relates to a method of assessing the likelihood of a subject having breast cancer or a precancerous condition associated with breast cancer. The present invention also relates to a method of determining whether treatment of breast cancer in a subject is required, and to a chemotherapeutic agent for use in the treatment of a subject in need of said treatment.
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour le typage de tissu ou de cellule, p.ex. sondes d’antigène leucocytaire humain [HLA]
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
A telescope including an optical alignment system. The telescope has a light collecting aperture, an imaging region for an imaging sensor, and comprises a plurality of optical elements between the light collecting aperture and the imaging region. The optical alignment system comprises a diffraction pattern on a surface of one of the optical elements, a light source to illuminate the diffraction pattern, and a metrology system to receive diffracted light from the light source after diffraction by the diffraction pattern. The metrology system is configured to characterize a wavefront of the diffracted light for determining an optical alignment of the telescope.
G02B 23/06 - Télescopes ou lunettes d'approche, p.ex. jumelles; Périscopes; Instruments pour voir à l'intérieur de corps creux; Viseurs; Pointage optique ou appareils de visée comprenant des prismes ou des miroirs ayant une action de mise au point, p.ex. miroir parabolique
G02B 26/06 - Dispositifs ou dispositions optiques pour la commande de la lumière utilisant des éléments optiques mobiles ou déformables pour commander la phase de la lumière
Embodiments of this disclosure are directed to devices that allow for adjusting of device parameters in a manner that does not involve power dissipation in an essential way. Thus, power demands when such devices are used in applications can be insignificant. This applies to both springs and inerters, which constitute basic lossless building blocks of mechanical device systems, and are analogues of inductors and capacitors in electrical circuits. Embodiments of this disclosure are also directed to a lossless adjustable 2-port transformer, and realization of mechanical translational and rotary transformers are set forth in the following. Embodiments of this disclosure allow for reduction of power demands in adjusting device parameters.
There is provided a micro electrical mechanical systems device package comprising: a first vacuum enclosure comprising a first enclosure wall; a micro electrical mechanical systems device being positioned within the first vacuum enclosure on a first side of the first enclosure wall; and a second vacuum enclosure, the second side of the first enclosure wall being within the second vacuum enclosure. Advantageously, the first vacuum enclosure is entirely within the second vacuum enclosure.
THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (Royaume‑Uni)
CAMBRIDGE ENTERPRISE LIMITED (Royaume‑Uni)
Inventeur(s)
Berry, Colin
Ford, Thomas J.
Davenport, Anthony P,
Abrégé
The invention provides means of diagnosing and treating microvascular angina (MVA). Diagnostic applications of intra-coronary guidewires are provided. Treatment of MVA patients with zibotentan is disclosed. The MVA patient can be identified and selected for treatment via the diagnostic applications provided.
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
73.
Tissue Equivalent Tubular Scaffold Structure, and Methods Of Production Thereof
The present invention provides tissue equivalent scaffold structures and methods of production thereof. Such methods include providing a casting chamber comprising an elongate mould portion, axially disposing a lumen template within the elongate mould portion, and at least partly filling the casting chamber with a gel casting material comprising a matrix of fibrils or fibres and an interstitial fluid phase, such that a portion of the lumen template extends above the casting material. The fluid phase of the gel is allow to flow axially out of the elongate mould portion, in a restricted manner, thereby resulting in axial densification of the gel casting material to form a tissue equivalent tubular scaffold. Tissue equivalent scaffold structures according to the present invention are able to support cell populations both within the walls and on the surface of the construct. They have enhanced mechanical strength due to increased collagen density, and are customisable in terms of luminal diameter and wall thickness. They may find application in tubular tissue engineering.
B29C 39/10 - Moulage par coulée, c. à d. en introduisant la matière à mouler dans un moule ou entre des surfaces enveloppantes sans pression significative de moulage; Appareils à cet effet pour la fabrication d'objets de longueur définie, c. à d. d'objets séparés en incorporant des parties ou des couches préformées, p.ex. coulée autour d'inserts ou sur des objets à recouvrir
We disclose herein a hetero-structure comprising: a curved material; at least one layer of a first material rolled around the curved material; at least one intermediate layer rolled on the at least one layer of the first material; and at least one layer of a second material rolled around the at least one intermediate layer.
H10K 30/30 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire comprenant des hétérojonctions de masse, p. ex. des réseaux interpénétrés de domaines de matériaux donneurs et accepteurs
H10K 30/53 - Dispositifs photovoltaïques [PV] sous forme de fibres ou de tubes, p. ex. fibres photovoltaïques
H10K 30/65 - Dispositifs à effet de champ sensibles à la lumière, p. ex. phototransistors
H10K 50/135 - OLED ou diodes électroluminescentes polymères [PLED] caractérisées par les couches électroluminescentes [EL] comprenant des ions mobiles
H10K 50/10 - OLED ou diodes électroluminescentes polymères [PLED]
H10K 71/12 - Dépôt d'une matière active organique en utilisant un dépôt liquide, p. ex. revêtement par centrifugation
G01N 27/12 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de la réaction avec un fluide
H01G 9/00 - Condensateurs électrolytiques, redresseurs électrolytiques, détecteurs électrolytiques, dispositifs de commutation électrolytiques, dispositifs électrolytiques photosensibles ou sensibles à la température; Procédés pour leur fabrication
This invention relates to the methods for the identification and isolation of cancer stem cells from cultured cancer cell lines. Cell line-derived cancer stem cells isolated using the present methods may be useful, for example, in assays to screen compounds for anti-cancer stem cell activity and in target discovery methods for identifying novel expressed genes and druggable targets. The invention also relates to the screening of compounds for activity against cell line-derived cancer stem cells.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/103 - Dispositifs de mesure pour le contrôle de la forme, du dessin, de la dimension ou du mouvement du corps ou de parties de celui-ci, à des fins de diagnostic
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
A61B 5/107 - Mesure de dimensions corporelles, p.ex. la taille du corps entier ou de parties de celui-ci
Consorzio Nazionale Interuniversitario Per Le Telecomunicazioni (Italie)
Cambridge Enterprise Limited (Royaume‑Uni)
Inventeur(s)
Ferrari, Andrea C.
Romagnoli, Marco
Midrio, Michele
Montanaro, Alberto
Sorianello, Vito
Abrégé
An RF transmitter comprising an optical source configured to generate a pair of optical lines separated by an RF carrier frequency. The transmitter may comprise a graphene photodetector having at least two electrical contacts; a transmit antenna coupled to a first of the electrical contacts; and an electrical data signal input connected to a second of the electrical contacts. The graphene photodetector is illuminated by the optical source; it may comprise a graphene photo-thermal effect (PTE) photodetector or a bolometric photodetector. A corresponding receiver is also described.
H04B 10/40 - Systèmes de transmission utilisant des ondes électromagnétiques autres que les ondes hertziennes, p.ex. les infrarouges, la lumière visible ou ultraviolette, ou utilisant des radiations corpusculaires, p.ex. les communications quantiques Émetteurs-récepteurs
H04B 1/38 - TRANSMISSION - Détails des systèmes de transmission non caractérisés par le milieu utilisé pour la transmission Émetteurs-récepteurs, c. à d. dispositifs dans lesquels l'émetteur et le récepteur forment un ensemble structural et dans lesquels au moins une partie est utilisée pour des fonctions d'émission et de réception
A Wavelength Division Multiplexing (WDM) for an optical fibre comprising a set of optical inputs, one for each wavelength of a WDM optical signal to be transmitted, a graphene electro-absorption modulator (EAM) for each optical input to modulate light from the optical input, and one or more drivers to drive each graphene electro-absorption modulator. The drivers have a data input, a low pass filter to low-pass filter data from the data input to provide low pass filtered data, and an output to drive each graphene electro-absorption modulator with a combination of the low pass filtered data and a bias voltage. The bias voltage is configured to bias the graphene EAM into a region in which, e.g., when the transmission of the graphene electro-absorption modulator increases the effective refractive index for the modulated light decreases and vice-versa to pre-chirp to the modulated light to compensate for dispersion in the fibre.
H04B 10/2513 - Dispositions spécifiques à la transmission par fibres pour réduire ou éliminer la distorsion ou la dispersion due à la dispersion chromatique
79.
MYC, CYCLIN T1 AND/OR CDK9 FOR USE IN THE TREATMENT OF DEGENERATIVE HEART AND CNS DISORDERS
The invention relates to expression of the transcription factor Myc and/or pTEF-b and their use as medicaments for inducing proliferation in cells with limited proliferative potential, such as cardiomyocytes. Also described are methods for the prevention and treatment of diseases, such as heart disease, associated with the loss of cells or cell death.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
80.
SUPERCONDUCTING WIRE AND METHOD OF FORMING THE SAME
Provided is a superconducting wire. The superconducting wire comprises a substrate, a superconducting film on the substrate and a pinning center in the superconducting film. The superconducting film includes Y1-xRExBCO and the pinning center has an additive of Ba2YNbO6.
H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par ou de leurs parties constitutives
The invention relates to a method of manufacturing a heart valve, comprising: a step of injection moulding a first part (110) of the heart valve from a first block-copolymer, wherein the injection moulding is performed at a temperature below an order-disorder transition temperature of the block copolymer, such that a phase structure is present in the molten block-copolymer; a step of injection moulding a second part (114) of the heart valve from a second block-copolymer that is different to the first block-copolymer, by over-moulding over the first part (110) to form an over-moulded structure, wherein the injection moulding is performed at a temperature below order-disorder transition temperatures for the first and second block copolymers, such that a phase structure is present in the molten second block-copolymer and remains present in the first block-copolymer; and a step of cooling the over-moulded structure, without heating it above the order-disorder transition temperatures between the step of injection moulding the second part (114) and the step of cooling, so as to preserve an arrangement of the phase structures created during the steps of injection moulding and produce anisotropic physical properties in the second part (114). The invention also relates to the thus manufactured heart valve.
B29C 45/16 - Fabrication d'objets multicouches ou polychromes
B29C 45/00 - Moulage par injection, c. à d. en forçant un volume déterminé de matière à mouler par une buse d'injection dans un moule fermé; Appareils à cet effet
A method for recycling lead-containing waste comprises: (a) dissolving the lead-containing waste in an aqueous solution of a first acid to form a solution of a first lead salt; (b) adding a second acid to the solution of the first lead salt to form a lead-depleted solution and a precipitate of a second lead salt; and (c) converting the precipitate of the second lead salt into leady oxide, wherein the first lead salt has a higher solubility in water than the second lead salt. The method may be used for recycling spent lead-acid battery paste.
A device and a method is provided for profiling particles such as proteins. The device comprises: a liquid chromatography column (16) in a mixture separation module (10); a fractionation device (22, 24) and a plurality of microfluidic analysis modules (26, 28) in a microfluidic network (14). The microfluidic analysis modules are configured to provide multi-dimensional analysis of the particles. Furthermore, a fluidic flow adaptor (20) allows for controlled flow between separator (16) and the microfluidic network to provide a continuous fluid flow.
The invention relates to the production of graft-mediated hybrid monocotyledonous plants. Methods for the production of such plants are disclosed herein.
This invention relates to the finding that FAMIN (fatty acid metabolism-immunity nexus; LACC1, C13orf31)) is a trifunctional purine salvage enzyme that displays a unique combination of adenosine deaminase, purine nucleoside phosphorylase and methylthioadenosine phosphorylase activities. Methods of measuring FAMIN activity and screening for FAMIN modulators are provided that comprise determining the adenosine deaminase activity, purine nucleoside phosphorylase activity and/or methylthioadenosine phosphorylase activity of an isolated FAMIN protein.
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une transférase
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase
This invention relates to the finding that inhibition or inactivation of FAMIN (‘fatty acid metabolism-immunity nexus’; C13orf31; LACC1 (laccase domain containing 1)) reduces tumourigenesis and stimulates cell-mediated immune responses. Method of treating cancer or stimulating cell-mediated immune responses in an individual by reducing FAMIN activity in the individual are provided. Also provided are methods of activating T cells in vitro using FAMIN deficient immune cells and stimulating cell-mediated immune responses comprising administering (a) a population of FAMIN deficient immune cells; or (b) a population of T cells activated in vitro by a population of FAMIN deficient immune cells.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/708 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p.ex. adénosine, acide adénylique ayant des groupes oxo liés directement au système cyclique purine, p.ex. guanosine, acide guanylique
A flow apparatus for detecting a component on a surface is provided. The flow apparatus, comprising an inlet for receiving a solution of the components to be detected; a detection chamber in fluid connection with and downstream from the inlet, and in fluid connection with a downstream outlet, wherein the internal surface of the detection chamber comprises a plurality of detection zones and the detection zones are configured to adhere to the component to be detected such that the component is immobilised in the detection zones; a detector for detecting components immobilised on each of the detection zones; and a director for directing the flow of the solution of the components to each of the detection zones in sequence, wherein the director is provided by flow rates.
The invention relates to the grafting of perennial monocots such as bananas and oil palms. Processes for the production of such plants are disclosed herein.
A method of optically characterizing individual molecules/molecular complexes, or other particles, in solution. The method comprises flowing a solution comprising the molecules/molecular complexes into an imaging region of a microfluidic channel, wherein the imaging region of the microfluidic channel has a first lateral dimension of greater than 1 μm in an x-direction wherein the x-direction is perpendicular to a direction of the flow; capturing a succession of images of the individual molecules/molecular complexes in the imaging region; tracking movement of the individual molecules/molecular complexes in at least the x-direction in the imaging region using the succession of images; and characterizing the individual molecules/molecular complexes from the tracked movement. In some implementations the characterizing comprises determining a diffusion coefficient of the molecules/molecular complexes from the tracked movement.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
G01N 15/02 - Recherche de la dimension ou de la distribution des dimensions des particules
A method of increasing the interference contrast in interferometric scattering optical microscopy. The method comprises providing a particle detection region comprising a chamber or channel having a boundary defined by one or more interfaces, illuminating a particle in the particle detection region with coherent light using an objective lens such that the light is reflected from the interface and scattered by the particle, capturing the reflected light and the scattered light using the objective lens, and providing the captured reflected and scattered light to an imaging device to image interference between the reflected light and the scattered light. The particle is illuminated by coherent light at an oblique angle to the interface.
A magnetic particle (30, 70) has a layered structure (6, 56) between a top surface of the particle and an opposed bottom surface of the particle. Layers of the structure include one or more nonmagnetic layer(s) and one or more magnetized layer(s). The ratio of a lateral dimension of the one or more magnetized layers to the aggregate thickness of the magnetized layer or layers is greater than 500. A plurality of such magnetic particles (30, 70) can be functionalised and marked with readable codes (16, 66) corresponding to the functionalisation, for use for performing assays such as bioassays.
H01F 10/26 - Pellicules magnétiques minces, p.ex. de structure à un domaine caractérisées par le substrat ou par les couches intermédiaires
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
92.
COMPOSITE LIGHT HARVESTING MATERIAL, DEVICE, AND METHOD
King Abdulaziz City for Science and Technology (Arabie saoudite)
Inventeur(s)
Rao, Akshay
Ehrler, Bruno
Friend, Richard Henry
Tabachnyk, Maxim
Abrégé
A photovoltaic device and method utilizing a light harvesting device and a photovoltaic cell; wherein the light harvesting device includes an organic semiconductor photoactive layer capable of multiple exciton generation with a luminescent material dispersed therein; wherein the bandgap of the luminescent material is selected such that the triplet excitons, formed as a result from the multiple exciton generation in the organic semiconductor, can be transferred from the organic semiconductor into the luminescent material non-radiatively via Dexter Energy Transfer; a photovoltaic cell disposed in an emissive light path of the luminescent material and having a first photoactive layer, wherein the bandgap of the luminescent material matches or is higher than the bandgap of the first photoactive layer.
H01L 25/16 - Ensembles consistant en une pluralité de dispositifs à semi-conducteurs ou d'autres dispositifs à l'état solide les dispositifs étant de types couverts par plusieurs des groupes principaux , ou dans une seule sous-classe de , , p.ex. circuit hybrides
H01L 51/44 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement en énergie électrique, soit comme dispositifs de commande de l'énergie électrique par ledit rayonnement - Détails des dispositifs
H01L 51/50 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés pour l'émission de lumière, p.ex. diodes émettrices de lumière organiques (OLED) ou dispositifs émetteurs de lumière à base de polymères (PLED)
H01L 31/055 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails adaptés comme dispositifs de conversion photovoltaïque [PV] Éléments optiques directement associés ou intégrés à la cellule PV, p.ex. moyens réflecteurs ou concentrateurs de lumière où la lumière est absorbée et réémise avec une longueur d’onde différente par l’élément optique directement associé ou intégré à la cellule PV, p.ex. en utilisant un matériau luminescent, des concentrateurs fluorescents ou des dispositions de convers
H01L 31/028 - Matériaux inorganiques comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des éléments du groupe IV de la classification périodique
H01L 31/0304 - Matériaux inorganiques comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des composés AIIIBV
H01L 31/032 - Matériaux inorganiques comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des composés non couverts par les groupes
H01L 51/42 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement en énergie électrique, soit comme dispositifs de commande de l'énergie électrique par ledit rayonnement
A photodetector comprising an optical waveguide structure comprising at least three stripes spaced from one another such that a slot is present between each two adjacent stripes of the at least three stripes. A graphene absorption layer is provided over or underneath the at least three stripes. There is an electrode for each stripe, over or underneath the graphene absorption layer. The photodetector is configured such that two adjacent electrodes are biased using opposite polarities to create a p-n junction effect in a portion of the graphene absorption layer. In particular the portion of the graphene absorption layer is located over or underneath each respective slot between said each two adjacent stripes.
H01L 31/103 - Dispositifs sensibles au rayonnement infrarouge, visible ou ultraviolet caractérisés par une seule barrière de potentiel ou de surface la barrière de potentiel étant du type PN à homojonction
H01L 31/028 - Matériaux inorganiques comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des éléments du groupe IV de la classification périodique
H01L 31/112 - Dispositifs sensibles au rayonnement infrarouge, visible ou ultraviolet caractérisés par un fonctionnement par effet de champ, p.ex. phototransistor à effet de champ à jonction
94.
FIELD-EFFECT TRANSISTOR FOR SENSING TARGET MOLECULES
A field-effect transistor for sensing target molecules, the field-effect transistor comprising: a substrate; an electric field sensitive layer on the substrate; a hexagonal boron nitride layer comprising a first surface and a second surface, wherein the first surface of the hexagonal boron nitride layer is on the electric field sensitive layer and wherein the second surface of the hexagonal boron nitride layer is functionalized with a plurality of receptor molecules; two or more electrical contacts wherein each of the electrical contacts are in electrical contact with the electric field sensitive layer.
A bulk superconductor device is disclosed, comprising a single grain RE-BCO element incorporating reinforcing fibres. The single grain (RE)BCO element comprises RE-211 pinning sites disposed in a RE-123 matrix and further comprises Ag. The reinforcing fibres comprise a ceramic such as SiC and a refractory metal such as W. The reinforcing fibres comprise a core formed of the refractory metal and a ceramic cladding surrounding the core. The device may be manufactured by a top seeded melt growth process or by a top seeded infiltration growth process.
H01L 39/12 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails caractérisés par le matériau
H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par ou de leurs parties constitutives
96.
INTEGRATED CLOSED-LOOP MEDICATION DELIVERY WITH ERROR MODEL AND SAFETY CHECK
A closed-loop system for insulin infusion overnight uses a model predictive control algorithm (“MPC”). Used with the MPC is a glucose measurement error model which was derived from actual glucose sensor error data. That sensor error data included both a sensor artifacts component, including dropouts, and a persistent error component, including calibration error, all of which was obtained experimentally from living subjects. The MPC algorithm advised on insulin infusion every fifteen minutes. Sensor glucose input to the MPC was obtained by combining model-calculated, noise-free interstitial glucose with experimentally-derived transient and persistent sensor artifacts associated with the FreeStyle Navigator® Continuous Glucose Monitor System (“FSN”). The incidence of severe and significant hypoglycemia reduced 2300- and 200-fold, respectively, during simulated overnight closed-loop control with the MPC algorithm using the glucose measurement error model suggesting that the continuous glucose monitoring technologies facilitate safe closed-loop insulin delivery.
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p.ex. compteurs de goutte-à-goutte électriques ou électroniques
A61B 5/1495 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang Étalonnage ou test des sondes in vivo
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang
A61M 5/142 - Perfusion sous pression, p.ex. utilisant des pompes
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
97.
Human Polarised Three-Dimensional Cellular Aggregates
Human polarised three-dimensional cellular aggregates generated in vitro from one or more human pluripotent stem cells are provided. Methods for obtaining human polarised three-dimensional cellular aggregates and cells obtained from the human polarised three-dimensional cellular aggregates are also provided.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
A method is provided of controlling the functionality of a substrate containing at least one nanopore. The method includes the steps of: introducing to the substrate a solution containing a molecular construct having a body formation which defines an aperture and a tail formation extending from the body formation; applying a potential difference across the substrate to thread the tail formation through the nanopore thereby docking the molecular construct to the substrate with the aperture aligned with the nanopore such that the sleeve formation lines the nanopore; and expelling the molecular construct from the substrate by varying the potential difference. A DNA construct for docking to a substrate having a nanopore is also provided, the construct having a body formation which defines an aperture, and a tail formation extending from the body formation for threading through the nanopore to dock the construct to the substrate with the aperture and nanopore in alignment.
The present invention relates to methods of working sheet metal, and sheet metal working apparatus for performing such methods. Such methods include steps of providing a sheet metal workpiece having first and second surfaces opposed to each other and at least one edge, bending the workpiece to form at least a first sidewall portion defined between the edge and a basal region, the first sidewall portion thereby defining a curved fold region in the sheet metal workpiece adjacent the first sidewall portion. Following this, first anvil tool and a first forming tool are provided for contact with and constraint of the first and second surfaces of the sheet metal workpiece respectively. The forming tool and/or the anvil tool are then progressively slid along the curved fold region to cause shear material transfer in the curved fold region to further deform the curved fold region. Such methods can allow for formation of components of similar shape as made at present by deep drawing methods, but with less wastage of the starting material.
B21D 19/04 - Mise en forme ou autres traitements des bords, p.ex. des bords des tubes par des outils à action continue se déplaçant le long du bord en forme de rouleaux
B21D 5/01 - Cintrage des tôles le long de lignes droites, p.ex. pour former un pli simple entre des marteaux et des enclumes ou butées
B21D 5/06 - Cintrage des tôles le long de lignes droites, p.ex. pour former un pli simple par un procédé d'étirage dans lequel les pièces à travailler sont mises en forme par passage entre des matrices ou des rouleaux, p.ex. fabrication de profilés
Flow apparatuses comprising a separation channel, a downstream flow separator, a detection zone, an observation zone, and a waste channel. The separation channel has first and second flows in contact and allows lateral movement of components between contacting first and second flows. The downstream flow separator is in communication with the separation channel and diverts a part of the first fluid flow, the second fluid flow, or both, from the separation channel. The detection zone comprises a detection channel downstream of and in communication with the flow separator and configured to receive a plurality of diverted flows from the flow separator and a label channel configured to label the diverted flows from the flow separator. The observation zone is configured to record an analytical signal indicative of the quantity and the electrical properties of the component. The waste channel is at the downstream end of the observation zone.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
G01N 15/02 - Recherche de la dimension ou de la distribution des dimensions des particules
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p.ex. utilisation de bandes de papier indicateur
G01N 15/00 - Recherche de caractéristiques de particules; Recherche de la perméabilité, du volume des pores ou de l'aire superficielle effective de matériaux poreux
brevets
